131I-Herceptin对乳腺癌细胞株的体外杀伤效应

南方医科大学学报 ›› 2005, Vol. 25 ›› Issue (06): 663-666.

¹³¹I-Herceptin对乳腺癌细胞株的体外杀伤效应

林菁, 罗荣城, 李爱民, 张军一, 吕成伟, 严晓

南方医科大学南方医院肿瘤中心, 广东, 广州, 510515

出版日期:2005-06-20 发布日期:2005-06-20
基金资助:
收稿日期:2005-1-3。
基金项目:广东省自然科学基金(037050)
作者简介:林菁(1973- ),女,在读硕士,主要研究方向为肿瘤生物治疗

Killing effect of ¹³¹I-Herceptin on breast cancer cell lines in vitro

LIN Jing, LUO Rong-cheng, LI Ai-min, ZHANG Jun-yi, LU Cheng-wei, YAN Xiao

南方医科大学南方医院肿瘤中心, 广东, 广州, 510515

Online:2005-06-20 Published:2005-06-20

摘要/Abstract

摘要： 目的研究核素¹³¹I标记Herceptin对Her-2表达阳性乳腺癌细胞株的特异性杀伤作用。为放射免疫导向治疗奠定基础。方法应用IODO-GEN方法将¹³¹I标记于抗Her-2单克隆抗体Herceptin,用MTT法检测¹³¹I-Herceptin对SK-BR-3、MCF-7、A5493种细胞株体外生长的抑制作用。结果 ¹³¹I-Herceptin的免疫活性与Herceptin无差异;¹³¹I-Herceptin对Her-2表达阳性的肿瘤细胞株的杀伤作用较Herceptin、¹³¹I明显增强(P<0.05),对于Her-2表达阴性或弱阳性的肿瘤细胞株无明显杀伤作用。结论 ¹³¹I-Herceptin可特异性杀伤Her-2表达阳性的肿瘤细胞。

Abstract: Objective To study the specific killing effect of ¹³¹I-labeled Herceptin on breast cancer cell lines positive for Her-2 expression. Methods Anti-Her-2 monoclonal antibody Herceptin was labeled with ¹³¹I by means of IODO-GEN, and the killing effects of Herceptin on SK-BR-3, MCF-7 and A549 cell lines expressing Her-2 were evaluated with MTT assay. Results ¹³¹I-Herceptin had immunoactivity had to that of Herceptin but possessed stronger killing effects on the cell lines expressing Her-2 than Herceptin and ¹³¹I used alone (P<0.05). Its killing effect on cell lines negative or only weakly positive for Her-2 expression was similar to that of ¹³¹I and Herceptin. Conclusion ¹³¹I-Herceptin can specifically kill Her-2-positive cancer cells in vitro.

中图分类号:

R737.9

林菁, 罗荣城, 李爱民, 张军一, 吕成伟, 严晓. ¹³¹I-Herceptin对乳腺癌细胞株的体外杀伤效应[J]. 南方医科大学学报, 2005, 25(06): 663-666.

LIN Jing, LUO Rong-cheng, LI Ai-min, ZHANG Jun-yi, LU Cheng-wei, YAN Xiao. Killing effect of ¹³¹I-Herceptin on breast cancer cell lines in vitro[J]. Journal of Southern Medical University, 2005, 25(06): 663-666.

参考文献

[1] Hayes DF, Thor AD. C-erbB-2 in breast cancer:Development of a clinically useful marker[J]. Semin Oncol, 2002, 29(3):231-45.
[2] Fraker PJ, Speck JR. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4,6-tetrachloro-3a,6adiphrenylglycoluril [J]. Biochem Biophys Res Commun, 1978, 80(4):849-57.
[3] Loosdrecht AA, Nennie E, Ossenkoppele GJ, et al. Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay, A methodological study[J]. J Immunol Methods, 1991, 141(1):15-22.
[4] CarterP, PrestaL, GormanCM, et al. Humanization ofan antip185HER2 antibody for human cancer therapy [J]. Proc Natl Acad Sci USA, 1992, 89(10):4285-9.
[5] Hadded E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 120 patients:a multicenter phase 1-2 clinical trial [J]. Blood, 2001,97(6):1590-97.
[6] vander Kolk LE, Gettitsen W, Baars J, et al. Phage Ⅰ / Ⅱ clinical trial to evaluate the safety of a combination of a chimeric anti-CD20monoclonal antibody and G-CSF given weekly to patienta with relapsed B cell lymphoma [J]. Blood, 1997, 90:512a.
[7] Kimby E, Geisler C, Hagberg H, et al. Rituximab as single agent and in combination with interferon-α as treatment of untreated and first relapse follicular of other low-grade lymphomas [J]. Blood, 2000,96 (Suppl 1):577a.
[8] Denard S J, O’Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody [J].Anticancer Res, 1997, 17(3B):1745-5 1.
[9] Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograhs[J]. Cancer Res, 1998, 58(13):2825-31.
[10] Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of Her-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers [J]. Oncogene, 1999, 18(13):2241-51.
[11] Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenographs on therapy with humanized monoclonal antibody to Her-2 receptor and DNA-reactive drugs [J]. Oncogene, 1998, 17(17):2235-49.

[1]	李新安；安靓； . 外源性基因经乳腺导管注射在大鼠乳腺组织中表达的机制研究[J]. 南方医科大学学报, 2006, 26(12): 1774-.
[2]	吴武军；曾健；潘承恩； . 活性炭-表阿霉素混悬液对乳腺癌腋窝淋巴结转移的治疗作用[J]. 南方医科大学学报, 2006, 26(12): 1812-1814.
[3]	康华峰；王西京；刘小旭；代志军；薛锋杰；薛兴欢；. 塞来昔布预防大鼠乳腺癌发生及其机制[J]. 南方医科大学学报, 2006, 26(11): 1599-1602.
[4]	李贵平；张一帆；汪勇先；. 188Re-Herceptin免疫导向治疗乳腺癌的实验研究[J]. 南方医科大学学报, 2006, 26(10): 1455-1457.
[5]	徐学虎；苏榕；伍尚标；. 早期乳腺癌保乳手术36例疗效评价[J]. 南方医科大学学报, 2006, 26(09): 1378-1379.
[6]	王晓玉；林绍强；李君武； Wolfgang Kemmner；丁彦青；. 细胞表面唾液酸及其连接方式对乳腺癌细胞黏附的影响[J]. 南方医科大学学报, 2006, 26(06): 742-746.
[7]	王晓冰；杨清绪；裴小娟；. 乳腺浸润性癌血管生成相关因子的表达及其临床意义[J]. 南方医科大学学报, 2006, 26(06): 860-863.
[8]	胡孝渠；秦利；苏逢锡；姚和瑞；陈积圣；龚畅；郭巨江；于风燕；贾海霞；. 载体介导HER-2RNA干扰治疗乳腺癌研究[J]. 南方医科大学学报, 2006, 26(05): 570-572.
[9]	张淑群；张淑慧；薛兴欢；王西京；姜建涛； . Survivin siRNA协同5-FU抑制MCF-7细胞的增殖(英文)[J]. 南方医科大学学报, 2006, 26(03): 251-254.
[10]	范义湘；罗荣城；方永鑫；严晓； . 131I-Herceptin的制备、质控及在新西兰兔的生物分布[J]. 南方医科大学学报, 2006, 26(03): 361-.
[11]	徐蕾；白中红；许软成；闫辉；王方聚；罗荣城；. Her-2、EGFR、PS-2、ER在乳腺癌中的表达及其临床意义[J]. 南方医科大学学报, 2006, 26(02): 231-233.
[12]	谭科；范义湘；缪景霞；吕成伟；严晓；罗荣城；. Herceptin与阿霉素序贯应用对乳腺癌细胞的杀伤效应[J]. 南方医科大学学报, 2006, 26(02): 234-236.
[13]	崔斐, 罗荣城, 陈锦章, 陈斌, 黄宇贤. 紫杉醇联合Herceptin或表阿霉素治疗Her-2/neu阳性乳腺癌患者的临床疗效[J]. 南方医科大学学报, 2005, 25(12): 1533-1536.
[14]	李荣, 郑航, 罗荣城. HER2基因的克隆及其在MCF-7细胞中的表达[J]. 南方医科大学学报, 2005, 25(10): 1264-1267.
[15]	郑航, 罗荣城. TPS、CA-153和CEA联合检测对乳腺癌的诊断价值[J]. 南方医科大学学报, 2005, 25(10): 1293-1294,1298.

¹³¹I-Herceptin对乳腺癌细胞株的体外杀伤效应

Killing effect of ¹³¹I-Herceptin on breast cancer cell lines in vitro

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价